This edition of Quick Notes includes EU approval of Pfizer’s hemophilia B gene therapy Durveqtix, a positive EMA opinion on an expanded label for Wegovy, two new EMA draft guidelines on oligonucleotides and active substances, and an EMA paper on the data needed to show the equivalence of nasal products that contain the same active molecule.